Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,573 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06776757RecruitingPhase 1/Phase 2
Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Shenzhen, GuangdongAges 18–75 - NCT06791538Recruiting
Robotic vs. laparoscopic surgery for advanced stomach cancer
This trial compares robotic-assisted surgery to standard laparoscopic surgery for locally advanced stomach cancer. It aims to see which approach offers better outcomes and recovery for patients.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06793137RecruitingPhase 2
Antibiotics before surgery for advanced rectal cancer
This trial tests if taking antibiotics before standard treatment can improve outcomes for people with advanced rectal cancer that requires surgery.
São Paulo, São PauloAges 18 years+ - NCT06840067Recruiting
Carbon ion radiotherapy for pancreatic cancer
This trial tests a new type of radiation called carbon ion therapy for people with advanced pancreatic cancer (stages III–IV) that has spread or can't be removed by surgery. It's combined with standard chemotherapy (gemcitabine plus nituzumab) to see if it can help shrink tumors and improve outcomes.
Wuwei, GansuAges 18–80 - NCT06867822RecruitingPhase 1
Testing ProAgio for Advanced Colorectal Cancer
This trial tests a new drug called ProAgio for people with advanced or metastatic colorectal cancer. It aims to see if ProAgio can help shrink or slow the cancer when combined with standard treatments.
Birmingham, AlabamaAges 19 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other solid tumors
This trial tests an oral drug called TYRA-430 for people with advanced liver cancer (HCC) or other solid tumors that have changes in the FGF/FGFR pathway. It aims to see how safe the drug is and whether it can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06940518RecruitingPhase 2
Ivonescimab for advanced clear cell kidney cancer
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT07098026Recruiting
Herbal mixture plus chemo before surgery for advanced stomach cancer
This trial tests whether adding an herbal mixture (Shenqi Fuwei Mixture) to standard chemotherapy before surgery can help treat locally advanced stomach cancer. It is for people whose cancer has not spread to distant sites and who are healthy enough to undergo treatment and surgery.
Changsha, HunanAges 18–75 - NCT07101432RecruitingPhase 1
Radiation plus engineered NK cells for advanced head and neck cancer
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
Houston, TexasAges 18 years+ - NCT07183150Recruiting
Lymph node removal range for advanced stomach cancer
This study is looking at how far surgeons should remove lymph nodes during surgery for advanced stomach cancer. It may help doctors decide the best way to remove cancer while reducing side effects.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT07213570RecruitingPhase 2
Second-line regorafenib for advanced RAS-mutant colorectal cancer
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
Naples, ItalyAges 18 years+ - NCT07325721RecruitingPhase 2
Shorter radiation with a focused boost for high-risk prostate cancer
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
Charleston, South CarolinaAges 18 years+ - NCT07340489RecruitingPhase 2
Serplulimab for locally advanced cervical cancer
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07376538RecruitingPhase 2
Treating advanced breast cancer based on treatment response
This trial tests a personalized approach to treating breast cancer that has spread to nearby lymph nodes. Your surgery and radiation will be tailored to how well your cancer responds to initial chemotherapy or hormone therapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07401199Recruiting
AI predicts immunotherapy response in advanced stomach cancer
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
Fuyang, AnhuiAges 18 years+ - NCT07423078RecruitingPhase 2
Larynx preservation trial for advanced throat cancer
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07528209RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced rectal cancer
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) before surgery helps treat locally advanced rectal cancer better. The goal is to shrink tumors and improve survival while preserving bowel function when possible.
Guangzhou, GuangdongAges 18–75 - NCT07551362RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Gastric Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Shenzhen, GuangdongAges 18–75 - NCT07594925RecruitingPhase 2
Short-course radiation plus immunotherapy and chemotherapy for rectal cancer
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
TianjinAges 18–75 - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT07799935Recruiting
Tumor ablation after chemo for advanced pancreatic cancer
This study tests a procedure called irreversible electroporation (IRE), which uses electric pulses to destroy cancer cells, after chemotherapy for advanced pancreatic cancer that hasn't spread. It aims to control the tumor and improve outcomes in people who are not eligible for surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Birmingham, AlabamaAges 12 years+ - NCT07797816RecruitingPhase 2
Targeted drug combo with radiation for advanced bile duct cancer
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
Nanjing, JiangsuAges 18–80
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,573 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.